Plain-English translation of NCT07075718 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new type of eye implant called travoprost intracameral implant that is placed directly inside the eye to help lower eye pressure in people with glaucoma or ocular hypertension. The implant is designed to release medication slowly over time. Researchers want to see if this implant works as well as or better than the standard eye drops that people currently use, and whether it is safe.
Many people with glaucoma struggle to remember to use eye drops every day, and some don't respond well to drops alone. This trial exists to see if a long-acting implant could be a more convenient and effective option for managing eye pressure and protecting vision.
You likely qualify if…
You likely don't qualify if…
Depending on which group you're placed in, you will either receive a small implant placed in your eye during a brief procedure, or you will use prescribed eye drops twice daily. All participants will attend regular follow-up visits over 3 years to have their eye pressure checked, vision tested, and any side effects monitored. The trial compares how well the implant works compared to the standard eye drop treatment.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States